Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2016-09-26
Target enrollment:
Participant gender:
Summary
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with
Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.
The primary objective will be to establish the long term tolerability and safety profile of
BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF).
As a secondary objective the effects of long term treatment with BIBF 1120 on survival as
well as safety and efficacy parameters will be investigated in an open-label, not randomized,
un-controlled design.